78 results about "Anti complement" patented technology

Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

The present invention provides a novel treatment for senile dementia (Alzheimer's Type), comprising administering an anti-complement protein to a patient in need of such treatment in an amount sufficient to inhibit the complement cascade and thereby inhibit the production or enlargement of amyloid plaques in the brain of the patient. The present invention further provides pharmaceutical compositions comprising anti-complement protein, or derivatives thereof, and / or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms.

Provided is a flow cytometry method and kit composition for semi-quantitatively determining complement fixing antibodies (CFAbs). The said antigen specific CFAbs in the sample will react with the antigens on the solid carriers or the surfaces of target cells as well as the labeled complement or labeled anti-complement antibody at the same time; and the labeled target cell specific antibody will bind to the target cell surfaces. Then the sample is analyzed to determine the amount of complements fixed by CFAbs, especially the amount of complements fixed by CFAbs on the surfaces of particular target cells or donor specific HLA antigens pre-captured by corresponding antibodies fixed on solid microparticles for evaluating whether there is CFAbs and their relative concentration.

The invention belongs to the field of Chinese traditional medicines and relates to a new use of 8-0-4' lignan in preparing an anti-complement medicine. The compound 8-0-4' lignan is extracted from a Chinese medicinal herb eucommia bark, and in vitro experiments prove that the compound 8-0-4' lignan can inhibit cell hemolysis caused by the activations of classical and alternative pathways of a complement system, and has obvious inhibitory action on the activation of the classical and alternative pathways of the complement system; and the results of pharmacological tests prove that the compound 8-0-4' lignan has obvious anti-complement effect and low effective concentration. The compound 8-0-4' lignan of the invention can be further taken as an active ingredient for preparing a novel anti-complement medicine.

An extracorporeal device for inhibiting alternative complement pathway activation includes a support structure an anti-complement antibody disposed on or within the support structure and a first conduit for conducting blood of the subject to the anti-complement antibody. The anti-complement antibody can bind to the complement protein and remove the complement protein from the blood.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to a dipeptide compound represented by a formula I and a new use of the dipeptide compound in preparation of anti-complement drugs. According to the present invention, the dipeptide compound is separated from the ethyl acetate extraction position of the ethanol extract of the dry whole herb Viola yedoensis Makino, and results confirm that the dipeptide compound provides inhibition effects for the classical pathway and the alternative pathway of the complement system, wherein the inhibition effect on the classical pathway (CH50) is 0.21-0.23 mg / ml, and the inhibition effect on the alternative pathway (AP50) is 0.33-0.41 mg / ml; and the dipeptide compound can be adopted as the drug active component to be adopted to prepare the anti-complement drug so as to be further adopted to treat systemic lupus erythematosus, rheumatoid arthritis, acute respiratory distress syndrome and other diseases initiated by excessive activation of the complement system.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to an alkaloid compound represented by a formula I and a new use of the alkaloid compound in preparation of anti-complement drugs. According to the present invention, the alkaloid compound is separated from the ethyl acetate extraction position of the ethanol extract of the dry whole herb Viola yedoensis Makino, and results confirm that the alkaloid compound provides inhibition effects for the classical pathway and the alternative pathway of the complement system, wherein the inhibition effect on the classical pathway (CH50) is 0.16-0.31 mg / ml, and the inhibition effect on the alternative pathway (AP50) is 0.26-0.46 mg / ml; and the alkaloid compound can be adopted as the drug active component to be adopted to prepare the anti-complement drug so as to be further adopted to treat systemic lupus erythematosus, rheumatoid arthritis, acute respiratory distress syndrome and other diseases initiated by excessive activation of the complement system.

The invention belongs to the Chinese medicine field, in particular to a plant polysaccharide PS-1, the preparation method thereof and the application in the preparation of anti-complement medicine. The invention obtains PS-1 through separating and extracting from the water extract of Chinese herbal compound used for preventing severe acute respiratory syndrome (SARS) and composed of houttuynia cordata, chrysanthemum indicum L, artemisia capillaries, eupatorium fortune and Amomum tsao-ko in the proportion of 15:6:15:10:3; as proven in the experiment that PS-1 respectively has inhibition effect on the classical pathway and alternative pathway of the activation of complement, acts on the ingredients of C1q, C1r, C1s, C2, C3,C4,C5 and C9, and has no anticoagulative effect. The plant polysaccharide PS-1 can be further used as an active ingredient for the preparation of new anti-complement medicine.

The invention discloses a polysaccharide from Eucommia ulmoides leaves with anti-complement activity, and its method of extracting, separating and purifying, wherein, the polysaccharide from Eucommia ulmoides leaves with anti-complement activity is an acidic polysaccharide. The extraction method comprises the following steps: adding eucommia fragments in petroleum ether, reflowing and magnetic stirring, and extracting filtration; air drying the residues, then using hot water for boiling-refluxing extraction, filtering and removing the residues with gauze; extracting the extract, carrying out decompression condense; mixing the polysaccharide concentrate with waterless ethanol, standing for precipitation, and using centrifugation to obtain a alcohol precipitated polysaccharide. The separating and purifying method comprises the following steps: producing a polysaccharide solution from crude polysaccharide, extracting filtration, and using macroporous resin to decolour; removing protein by using Sevag method, mixing Sevag reagent with the polysaccharide sample uniformly, carrying out centrifugation, collecting supernatant and condensing, UV-scanning until no absorption peak; respectively dialyzing the crude polysaccharide solution; weighing polysaccharide to dissolve in distilled water, and eluting on a cellulose column to obtain the monomer component of refined polysaccharide. The method realizes the exploitation of folium cortex eucommiae resource, lays a foundation for the application in pharmacy industry, and serves the health of human.

The invention belongs to the field of traditional Chinese medicine, and relates to a new application of luteolin for preparing an anti-complement medicine. In the invention, the luteolin is separated and extracted from a traditional Chinese medicine formula used for preventing and treating severe acute respiratory syndrome (SARS); the traditional Chinese medicine formula consists of heartleaf houttuynia herb, wild chrysanthemum, herba artemisiae capillaries, fortune eupatorium herb and tsaoko with the weight ratio of 15: 6: 15: 10: 3; and experiments prove the anticomplement activity of the classical pathway and alternative pathway. The compound luteolin contained in the anticomplement medicine can be taken as an active ingredient for preparing a novel anticomplement medicine.

Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

The invention belongs to the technical field of medicaments and relates to a furan derivative and application thereof, in particular to a new furan derivative for treating immunologic diseases. The structural formula of the furan derivative is shown in the specifications, wherein an R group can be linear chain alkyl and branched chain alkyl having 2 to 11 carbon atoms. A compound has a stable structure and various clinically acceptable formulations can be prepared by matching the compound with an appropriate amount of pharmaceutical adjuvant. An immunology experimental result indicates that the compound has relatively high anti-complement activity and no activity difference between two formulations, so the compound has the advantages of relatively high activity, little medicament dosage and the like. The furan derivative and a preparation which is possibly developed by the furan derivative are mainly used for treating various diseases caused by over activation of a complement system. The R group is linear chain alkyl and branched chain alkyl having 2 to 11 carbon atoms.

The invention belongs to the field of Chinese medicinal pharmacy, and relates to new medicinal application of diphenol compounds of a formula 1. The diphenol compounds serving as active substances are extracted from Amomum tsao-ko Crevost et Lemaire fruits, and in vitro anti-complement activity evaluation experiments prove that the diphenol compounds have remarkable inhibiting effect on a classical pathway and an alternative pathway of a complement system. The inhibiting effect CH50 of the compounds on the classical pathway of the complement system is 61+ / -12 to 91+ / -19mug / ml, and the inhibiting effect AP50 on the alternative pathway is 58+ / -17 to 121+ / -18mug / ml. The diphenol compounds can be used for preparing anti-complement medicaments.

The invention relates to the preparation method of HBIG of human for mainline. The preparation method comprises the steps that: by a low-temperature ethanol separation method, firstly, FI + II + III precipitation is separated from mixed-immune plasma, then is put into water for injection to be dissolved for a second separation and the supernatant is filtered for a third separation to get FII precipitation; finally, the FII precipitation with a part by weight is put into 5-6 parts of water for injection to be dissolved, the pH is adjusted to be 4.00 minus or plus 0.05, the solution is filtered with a film, and processed by hyperfiltration and dealcoholization, aseptic filtration, virus-inactivating, degerming and split charging. The invention adopts the low-temperature ethanol, applies low pH incubation inactivation and nano-membrane virus to filter double virus inactivation / removal technique; each step has the reduction, inactivation, removal effects on the known probable virus in the blood; compared with the current intramuscular injection products, the purity of products, antibody titer, and the quality indicators such as the content of polymer and the content of protein which reduce the products, and anti-complement activity are all improved to a certain extent.

The invention provides the application of caffeoylquinic acid and its derivatives in the preparation of anti-complement drugs. The present invention extracts and separates the caffeoylquinic acid compounds obtained from Shamrock, through in vitro experiments, it is confirmed that the cell hemolysis caused by the activation of the classic pathway of the complement system is inhibited, indicating that there is an anti-complement effect. The activity is stronger than that of the total extract of S. sageris, and it is a kind of good complement inhibitor, which can be used to prepare new anti-complement drugs and treat various diseases caused by abnormal activation of complement, and has low effective concentration and low toxicity. The drug is safe, the source of raw materials is abundant, and it has great clinical application value. Caffeoylquinic acid and its derivatives are shown in the following structural formula I: Formula I wherein R1, R2, R3, or R4 can be the same or different, and they are H or caffeoyl respectively, provided that they cannot be H at the same time; R5 is H , CH3, CH2CH3 or CH2CH2CH2CH3.

The invention discloses an anti-keratin antibody detection method and an anti-keratin antibody regent box, and belongs to the method for detecting the characteristics of blood in body. The method provided by the invention can be operated as follows: the esophagus of a bandicoot can be made into a biological thin slice which can be taken as an antigen and coated in the reaction region of a piece of slide glass; blood serum to-be-detected is added in the reaction region and then added with complement after the incubation, rinsing and drying in a spanning way, then added with the fluorescent markers of anti-complement antibodies after the incubation, rinsing and drying in a spanning way, and then observed under a fluorescence microscope after the incubation, rinsing and drying in a spanning way; if the horny layer appears typical and regular line-shaped or lamellar fluorescence, the detection result is positive. The regent box provided by the utility model is filled with regents, cover glass and slide glass with biological thin slices, such as negative control serum, positive control serum, condensed phosphate buffer solution and the application solution of the fluorescent markers of complement and anti-complement antibodies. The method provided by the invention is better than the prior method in indicators such as sensitivity, specificity, negative predictive value and positive predicative value, therefore, the method has higher diagnosis value in diagnosing rheumatoid diseases.

The invention belongs to the field of traditional Chinese medicine and relates to a total cedar polysaccharide. The polysaccharide is a water-soluble crude polysaccharide extracted and prepared from Sabina pingii var.wilsonii branches and leaves, and the structural characteristics such as sugar content, uronic acid content, protein content, molecular weight distribution and monosaccharide composition of the polysaccharide are represented. Activity determination results indicate that the cedar polysaccharide has an obvious anticomplementary action, the half effective inhibition concentration of a complement activation classical pathway is up to 23-35 micro-g / ml, and the polysaccharide is equivalent to a positive control drug in heparin sodium activity. In addition, the level of mouse peritoneal macrophage cell secretion NO under LPS stimulation can be remarkably inhibited, and it is indicated that the total cedar polysaccharide has a very good anti-inflammatory effect. The total cedar polysaccharide can be used for preparing anti-complement, anti-inflammatory and other immunosuppressive related drugs.

The present invention belongs to the field of medicine, and relates to uses of a lignan compound (7S,8R)-dihydrodehydrodiconiferyl alcohol in preparation of anti-complement drugs. According to the present invention, a lignan compound (7S,8R)-dihydrodehydrodiconiferyl alcohol is separated from the dried root of a Helicteres plant Helicteres angustifolia L, and the modern pharmacological research method results confirm that the method provides strong inhibition effects for complement activation in the complement system classical pathway and the alternative pathway, wherein the CH50 value is 0.0032 mg / ml, the AP50 is 0.0077 mg / ml, and the compound can be used as the active component so as to be used for preparing anti-complement drugs.

The invention belongs to the field of pharmacy, and relates to a novel application of a flavan compound in preparing anti-complement medicines. According to the invention, a modern pharmacological screening method is applied, and researches are carried out upon anti-complement active substances in plant medicines. According to the invention, the flavan compound is obtained by separation from an n-butanol extract of a commelinaceae plant commelina and an n-butanol extract of a polygonum plant fagopyrum. With an in-vitro complement activity evaluation test, it is verified that the compound has high inhibition effect upon classical pathway and alternative pathway of a complement system. The CH50 of the inhibition effect of the compound upon the classical pathway of the complement system is 0.13 (plus or minus 0.03)-0.78 (plus or minus 0.06) mM, and the AP50 of the inhibition effect of the compound upon the alternative pathway of the complement system is 0.12 (plus or minus 0.01)-1.00 (plus or minus 0.15) mM. The compound can be used for preparing anti-complement medicines.

The invention belongs to the field of traditional Chinese medicine and relates to five homogeneous polysaccharides in Ficus pumila leaves, a preparation method thereof and a use thereof in the preparation of anti-complement drugs. Five homogeneous polysaccharide BL-PS1, BL-PS3, BL-PS4, BL-PS5 and BL-PS6 are separated from the traditional Chinese medicine Ficus pumila leaves for clearing heat and removing toxicity. The test shows that these homogeneous polysaccharides can inhibit the classical and bypass pathways of complement activation, and can be used as active components to prepare new anti-complement drugs.

The invention belongs to the field of Chinese pharmaceutical manufacturing, and relates to sesquiterpenoid compounds in a formula I and application of the sesquiterpenoid compounds to preparing anti-complement medicine. Five germacrane lactone sesquiterpenoid compounds are separated from petroleum ether extraction parts of dry whole-herb ethanol extracts of violaceae plants, namely, viola yedoensis makino, it is proved that suppression effects can be realized by the other compounds for classical pathways and alternative pathways of complement systems except for aristolactone (4) (which only is active for the classical pathways of the complement systems), and the germacrane lactone sesquiterpenoid compounds can be used for preparing the anti-complement medicine and further preparing medicine for treating complement-related diseases.

The present invention relates to the field of traditional Chinese medicine pharmacy, particularly to uses of aryl-substituted phenylpropanoid-based compounds in preparation of anti-complement drugs. According to the present invention, the aryl-substituted phenylpropanoid-based compounds 1-3 are extracted from the root of an Aquifoliaceae plant Ilexasprella by using an activity guide separation method, and the results of the classical pathway anti-complement activity evaluation test and the alternative pathway anti-complement activity evaluation test show that the compounds provide strong inhibition effects for the classical pathway and the alternative pathway of the complement system, wherein the inhibition effect on the classical pathway (CH50) is 0.032-0.059 mg / ml, and the inhibition effect on the alternative pathway (AP50) is 0.061-0.275 mg / ml; and the compounds can be used for preparing anti-complement drugs and further preparing drugs for treatment of complement-related diseases.

The invention provides application of codiaceae polysaccharide to an anti-complement drug. The codiaceae polysaccharide has complement activity, and the application of the codiaceae polysaccharide refers to the application of the codiaceae polysaccharide with the complement activity to the preparation of the anti-complement drug or / and an anti-complement health-care product. The invention discovers the remarkable inhibiting function of the codiaceae polysaccharide on the classical pathway complement activity and the alternative pathway complement activity for the first time and discloses the application of the codiaceae polysaccharide to the preparation of the anti-complement drug and the anti-complement health-care product, so that the excessive activation of a complement system can be inhibited and further the certain preventive and therapeutic effects on various diseases such as systemic lupus erythematosus, rheumatoid arthritis and acute respiratory distress syndrome caused by the excessive activation of the complement system are achieved.

The invention relates to the field of Chinese medicine production, in particular to use of quassin compounds in the preparation of an anti-complement drug. A modern pharmacological research method isadopted to study an anti-complement active substance in the fruit of Brucea javanica L. Merr, and obtain two quassin compounds from the ethyl acetate extract of Brucea javanica by active guide separation, that is a compound 1 Bruceine F and a compound 2 20-hydroxylbruceine E-2-beta-D-glucopyranoside. According to an in-vitro anti-complement drug test, the two compounds have different degrees of inhibition on a classical pathway and an alternative pathway of a complement system and can be used for preparing the anti-complement drug.